Sanofi, Regeneron show positive results for Zaltrap

Wednesday, April 27, 2011 02:13 PM

Partners Sanofi-Aventis and Regeneron Pharmaceuticals report positive results for a late stage study evaluating Zaltrap (aflibercept), a colorectal cancer candidate.  

The two companies announced that the phase III VELOUR trial evaluating Zaltrap, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer (mCRC).

George Yancopoulos, chief scientific officer at Regeneron, said "these findings are exciting given the limited second-line treatment options for patients with mCRC.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs